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mary profile we used the data of frequency by age and gender for this specialised 
profile obtaining this from the minimum joint data base of the hospital discharge. 
The profile of the pharmaceutical expenditure by age and gender was obtained 
from the pharmacy invoice, once the public contribution was deducted. The esti-
mated population in 10 years was obtained from the National Statistic Institute. 
(INE). Results: aging results in a cumulative annual rate for the period 2011-2021 
for public health expenditure growth of 5.34%. The aging effect implies a cumula-
tive annual rate in the period 2011-2021 of 6.43% and a decrease of -0.69% due to 
the range effect (decrease in population). Of all the segments, the largest increase 
is in the pharmaceutical costs with an accumulated increase of 8.81%, of which 
5,65% is in primary attention and 4,78% in specialised attention. ConClusions: 
According to our results, population growth or aging are determining aspects in 
public health expenditure increase. Using data directly from each region will explain 
the differences. In the case of Extremadura, the age factor is very important when 
increasing the pressure of the public health cost, having a special influence in the 
field of pharmaceutical expenditure and primary attention.
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objeCtives: As is the case with many of the Commonwealth of Independent 
Countries (CIS), since the collapse of the Soviet Union, both Kazakhstan and 
Uzbekistan have been re-building health care provision, and improving access 
to medications for their population. This study compares the two separate paths 
the countries have taken, and aims to establish the outcomes achieved by the 
two systems as well as the direction of future reforms. Methods: Secondary 
research focused on analysing the systems in place in the two countries, focus-
ing on drug provision. The study assessed the mechanisms in place, drawing 
comparisons between the two systems, with a particular focus on the outcomes 
achieved. Results: Uzbekistan provides medications free of cost for certain catego-
ries of patients, while in Kazakhstan, the government has approved a list of drugs 
that are provided for free as part of the guaranteed volume of free medical care. In 
both the cases these fall under an outpatient setting. Although the procurement of 
drugs is carried out mostly via tenders, Kazakhstan’s system involves establishing 
price ceilings. In Uzbekistan, retail and wholesale margins are controlled. Between 
2002-2012, public health expenditure as a percentage of total health expenditure 
rose from 54% to 58% in Kazakhstan and from 45% to 53% in Uzbekistan. Life expec-
tancy however, increased from 65.9 to 69.6 years in Kazakhstan and from 67.1 to 68.1 
years in Uzbekistan. ConClusions: With growing government health expendi-
ture, reflecting the expansion of the health care systems, the countries are likely 
to increasingly look into containing costs. Given that some pricing mechanism 
is already in place in Kazakhstan, it may consider implementing tighter pricing 
regulations, moving closer to those seen in Europe. In Uzbekistan, the government 
may potentially consider expanding the beneficiary categories while ensuring com-
petiveness within the tendering process.
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objeCtives: The Cervantes scale is a specific health-related-quality-of-life (HRQoL) 
questionnaire developed in Spanish women through and beyond menopause. The 
original 31-item scale was reduced to a less time consuming 16-item sort form: 
The Cervantes-SF. The aim of this work was to assess the psychometric properties 
of the Cervantes-SF in a routine clinical sample of perimenopause and postmeno-
pause women. Methods: Peri and postmenopause adult women were recruited in 
twelve outpatient clinics of Gynecology. All of the patients completed both scales, 
the 31-items form and the abridged version, however, order of administration was 
balanced equally to avoid administration bias. A sub-sample of 31 women answered 
the sort form within 1-2 weeks later (rete-test). Correlation between forms and test-
retest reliability were used to test measurement stability. Item analysis, internal 
consistency reliability, item-total and item-domain correlations and item correla-
tion with the generic Spanish version of the EQ-5D-3L questionnaire were also 
studied. Results: A sample of 215 women [mean age 55 years old (SD= 5.3)] was 
enrolled. Internal consistency was good (Cronbach’s a= 0.829) but slightly lower than 
that of the original scale (a= 0.895). Dimension reliabilities ranged between a= 0.636 
(Health) and a= 0.923 (Vasomotor). Correlations between extended and reduced 
subscales was high and significant in all cases (p< 0.001), ranging from r= 0.790 for 
Health to r= 0.872 for Vasomotor. Correlation between total scores was also high 
(r= 0.885) and no differences were found between mean scores (Effect size= 0.353). 
Short-form total score correlation with EQ-5D utility score was negative and signifi-
cant (r= -0.487) and also with EQ-5D Health VAS (r= -0.432). Test-retest correlation 
was high (r= 0.886). Completion of Cervantes-SF required half of the time than the 
original scale. ConClusions: The abridged 16-item Cervantes scale (Cervantes-SF) 
maintained the original psychometric properties. This version extends 51% of the 
original length, being faster to apply and making it specially suitable for routine 
medical practice.
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perspective) for the standard fertility treatment strategy is about 50M USD com-
pared to the fast track fertility treatment strategy at about 41M USD for a net budget 
impact of 9M USD. The average cost per patient per year (patient perspective) for 
the standard fertility treatment strategy is approximately 4,800 USD compared to 
the fast track fertility treatment strategy at an estimated 4,200 USD for a net budget 
impact of approximately 600 USD. Results vary upon user inputs. ConClusions: 
An Excel-based model was developed to assist managed care organizations and 
employers with the development of an optimal fertility benefit design. The model 
serves as an educational tool to evaluate various fertility benefit designs in terms 
of patient and financial outcomes.
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objeCtives: Older people are vulnerable to medicine-related adverse effects. In 
response to these concerns, prescribing indicators have been developed address-
ing: Potentially Inappropriate Medicines (PIMs), medicines with unfavourable risk-
benefit ratios and Potential Prescribing Omissions (PPOs), omission of indicated 
medicines with a clear benefit. Little is known about the impact of PIMs and PPOs 
on health care utilization. This study aims to determine the association between 
PIMs and PPOs and health care utilization. Methods: This is a retrospective cohort 
study of 2,051 community-dwelling participants in The Irish Longitudinal Study on 
Ageing (TILDA) aged ≥ 65 years with linked medication dispensing history from a 
national pharmacy claims database. PIM and PPO exposure in the 12 months prior 
to participants’ TILDA interviews was determined using validated prescribing indi-
cators: Screening Tool for Older Persons’ Prescriptions (STOPP), the Screening Tool 
to Alert doctors to Right Treatment (START), Beers’ criteria and Assessing Care of 
Vulnerable Elders (ACOVE) indicators. Outcome measures used were self-reported 
number of hospital visits (emergency department or inpatient admissions) and 
general practitioner (GP) visits in the previous year. Poisson regression models were 
used to determine the associations between PIMs and PPOs and these outcomes, 
adjusting for age, sex, education, number of medications, chronic conditions, and 
health insurance status. Results: Overall PIM prevalence was 19.8-52.7% and PPO 
prevalence was 43.6-44.8% depending on the screening tool applied. Independent 
of screening tool used, PIMs and PPOs were significantly associated with hospi-
tal visits. For example, the adjusted Incident Rate Ratio (IRR) for each additional 
STOPP PIM was 1.24 (95%CI= 1.15-1.35). With the exception of START PPOs, PIM and 
PPO exposure were also significantly associated with GP visits (adjusted IRR= 1.10 
(95%CI= 1.06-1.15) for each additional Beers’ PIM for example). ConClusions: PIM/
PPO exposure is independently associated with increased health care utilization, 
supporting application of PIM/PPO indicators as robust measures of health care 
quality and patient safety in relation to prescribed medications.
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objeCtives: Assisted reproductive therapy (ART) has increased dramatically in 
the US over the past several decades, nearly doubling from 1999 to 2008. Prior 
research has evaluated multiple outcomes from ART including newborn survival 
and birth weight as well as cost analyses measuring cost per live birth; despite 
robust information on ART as a whole there is no Colorado-specific data on neo-
natal intensive care unit (NICU) outcomes following ART and its economic impli-
cations. Methods: Using data from the Colorado Department of Public Health 
and Environment (CDPHE) - Colorado Birth Certificate Database from 2007-2012, 
we use multivariable logistic regression to determine if ART births are associ-
ated with a higher risk of NICU admission compared to non-ART (no fertility 
treatment) births. We compare the risk of NICU admission among the full birth 
cohort and a singleton-only cohort controlling for plural births and birth order. 
We use Colorado state Health Care Policy and Financing (HCPF) fiscal year 2007-08, 
Colorado Centre for Reproductive Medicine costs and Colorado State Medicaid 2012 
fee schedule data to estimate average NICU admission rates, total ART procedural 
costs and average costs of delivery, respectively. Results: 190,795 live births in 
2007-2012 were included into the birth cohort for analysis (12,666 ART births; 
178,129 non-ART births). ART births resulted in a 52% increased risk of being 
admitted to the NICU compared to non-ART births (OR 1.52 [95% CI 1.38,1. 69]); 
singleton-only ART births had a 39% greater risk of being admitted to the NICU 
compared with singleton non-ART births (OR 1.39 [95% CI 1.18,1. 65]). Average 
NICU admission costs were estimated at $ 6,165.78 per ART birth and $ 331.85 per 
non-ART birth. ConClusions: ART births in Colorado have a higher risk of NICU 
admission compared to non-ART births. The economic impact of NICU admissions 
is 18.6 times greater among ART births compared to non-ART births.
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objeCtives: To estimate the effect of demographic component in the evolution 
of public health expenditure of Extremadura in the period 2011-21 Methods: we 
estimated health expenditure profiles by age and gender in 2011. Then, we used 
population projections to calculate future health spending. To obtain those profiles 
we used data obtained from the information systems of Extremadura. For the pri-
